Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 22, Number 1—January 2016

Research

Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013

Ross L. CameronComments to Author , Kimberley Kavanagh, Jiafeng Pan, John Love, Kate Cuschieri, Chris Robertson, Syed Ahmed, Timothy Palmer, and Kevin G.J. Pollock
Author affiliations: Health Protection Scotland, Glasgow, Scotland, UK (R.L. Cameron, J. Love, S. Ahmed, K.G.J. Pollock); University of Strathclyde, Glasgow (K. Kavanagh, J. Pan, C. Robertson); Scottish Human Papillomavirus Reference Laboratory, Edinburgh, Scotland, UK (K. Cuschieri); University of Edinburgh, Edinburgh (T. Palmer)

Main Article

Table 6

Prevalence and odds of infection with HPV types 16 or 18 and for HPV cross-protective types among nonvaccinated women, by study year, Scotland, 2009–2013*

Study year No. women HPV 16 or 18
Cross-protective HPV types†
No. pos % Pos (95% CI) OR (95% CI) No. pos % Pos (95% CI) OR (95% CI)
2009 1,652 468 28.3 (26.2–30.6) 1 (reference) 211 12.8 (11.2–14.5) 1 (reference)
2010 1,012 310 30.6 (27.9–33.5) 1.13 (0.95–1.34) 139 13.7 (11.8–16.0) 1.10 (0.87–1.38)
2011 557 164 29.4 (25.8–33.4) 1.05 (0.85–1.29) 71 12.7 (10.2–15.8) 0.99 (0.74–1.32)
2012 245 78 31.8 (26.3–37.9) 1.18 (0.88–1.57) 28 11.4 (8.0–16.0) 0.88 (0.58–1.33)
2013 198 42 21.2 (16.1–27.4) 0.67 (0.47–0.96) 19 9.6 (6.2–14.5) 0.71 (0.44–1.17)

*HPV, human papillomavirus; OR, odds ratio; pos, positive.
†HPV 31, 33, or 45.

Main Article

TOP